Hyperglucagonemia following cisplatin treatment.
These studies were initiated to determine (1) if cisplatin (cis-DDP)-induced hyperglucagonemia is related to decreased hormone degradation, (2) the relationship between impaired kidney function associated with cis-DDP nephrotoxicity and hyperglucagonemia, and (3) the contribution of cis-DDP-induced hyperglucagonemia to disturbances in glucose metabolism in male F-344 rats. Administration of 5 or 7.5, but not 2.5, mg/kg cis-DDP iv increased fasting plasma immunoreactive glucagon (IRG) concentrations. Hyperglucagonemia following cis-DDP treatment was characterized by an increase in the biologically active or true pancreatic form of IRG as well as an increase in an extrapancreatic component. cis-DDP treatment (5 mg/kg) resulted in a prolonged half-life and a reduced rate of plasma disappearance of exogenous glucagon. Reducing cis-DDP nephrotoxicity, via mannitol pretreatment, resulted in a significant reduction in total, true pancreatic, and extrapancreatic plasma IRG. Other nephrotoxicants, such as glycerol or gentamicin, also resulted in hyperglucagonemia, indicating that the effects of cis-DDP on glucagon metabolism are also characteristic of other nephrotoxicants and, therefore, may be secondary to kidney toxicity. Despite marked hyperglucagonemia following cis-DDP treatment, neither severe fasting hyperglycemia nor increased hepatic and renal gluconeogenic enzyme activity was apparent in treated animals. This apparent discrepancy cannot be attributed to glucagon resistance at the target tissue level since cis-DDP-treated animals responded appropriately to exogenous glucagon. These results indicate that hyperglucagonemia following cis-DDP treatment (1) may be related to decreased glucagon degradation associated with impaired renal function and (2) does not markedly disrupt glucose homeostasis.